NCT06008522View on ClinicalTrials.gov

Safety and Feasibility of Immuno-OCT

NANot yet recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

September 1, 2024

Study Completion Date

March 1, 2025

Conditions
Colon CarcinomaBarrett EsophagusGastrointestinal Dysplasia
Interventions
DRUG

Bevacizumab-800CW

Imaging of fluorescently labeled Bevacizumab-800CW using OCT.

All Listed Sponsors
lead

University Medical Center Groningen

OTHER

NCT06008522 - Safety and Feasibility of Immuno-OCT | Biotech Hunter | Biotech Hunter